|Articles|November 1, 1999

The Clinical and Economic Impact of Pneumococcal Disease in the Pediatric Population
Volume 5
Issue 17 Suppl

Selected Abstracts

Download PDF: Selected Abstracts

Articles in this issue

over 26 years ago

Article

Participating Faculty

over 26 years ago

Article

Introduction

over 26 years ago

Article

Epidemiology of Pneumococcal Disease

over 26 years ago

Article

The Costs of Antimicrobial Treatment Failure in Acute Otitis Media

over 26 years ago

Article

Prevention of Pneumococcal Disease in High-Risk Pediatric Groups

over 26 years ago

Article

The Clinical Impact of Pneumococcal Conjugate Vaccines

over 26 years ago

Article

Economic Impact of Pneumococcal Conjugate Vaccine in Managed Care

over 26 years ago

Article

Into the Era of the Pneumococcal Conjugate Vaccine

over 26 years ago

Article

CME Quiz

over 26 years ago

Article

Bibliography

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

The Timing and Characteristics of Supplemental Indications for Medicines

ByYingying Zhu, PhD,Claire H. Brennan, BA,Haijun Tian, PhD,Josephine N. Tran, PharmD, MS,Peter J. Neumann, ScD,James D. Chambers, PhD,Pei-Jung Lin, PhD,Meng Li, PhD

July 6th 2026

Selected Abstracts

Articles in this issue

Related Content

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

The Timing and Characteristics of Supplemental Indications for Medicines

Trending on AJMC

Ebola Cases Top 1700 as Unpaid Health Workers Strike

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

FDA Expands Approval for VWD Prophylaxis in Children Younger Than 6

Gene Therapy Could Ease Wet AMD's Injection Burden: Carl Regillo, MD

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Selected Abstracts

Articles in this issue

Related Content

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

The Timing and Characteristics of Supplemental Indications for Medicines

Trending on AJMC

Ebola Cases Top 1700 as Unpaid Health Workers Strike

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

FDA Expands Approval for VWD Prophylaxis in Children Younger Than 6

Gene Therapy Could Ease Wet AMD's Injection Burden: Carl Regillo, MD

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies